ArticleBMJ open respiratory research2026
Functional respiratory imaging reveals early structural and functional airway responses to benralizumab in severe eosinophilic asthma.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenralizumab improves outcomes in severe eosinophilic asthma (SEA). We aimed to evaluate early effects of benralizumab on airway pathophysiology using functional respiratory imaging (FRI).
methodsIn this prospective, single-arm study, 20 adults with SEA underwent CT at baseline, 4 and 12 weeks. Coprimary endpoints were changes in specific airway volume (siVaw) and resistance (siRaw) at functional residual capacity (FRC) and total lung capacity (TLC) at 12 weeks. Imaging outcomes included mucus score/volume and air-trapping.
resultsAt week 12, siVaw increased at FRC by 0.16 mL/L (27%; 95% CI 0.01% to 0.31%; p = 0.02) and at TLC by 0.14 mL/L (14%; 95% CI 0.03% to 0.25%; p = 0.02); siRaw at TLC decreased by -0.41 kPa·s/L (-24%; 95% CI -0.80% to -0.01%; p = 0.04). siRaw at FRC increased (2.99 kPa·s/L; 95% CI -4.57 to 10.54; p=0.42), with a significant relative change (293%; p=0.03) that lost significance after excluding outliers. siVaw at FRC increased early (week 4: 0.19 mL/L; 33%; 95% CI 0.03% to 0.34%; p = 0.01). At week 12, the mucus score decreased by 0.41 (95% CI -0.67 to -0.14; p<0.01), and air-trapping by 5.5% (95% CI -8.8 to -2.1; p < 0.01). Changes in siVaw and mucus correlated with improvements in forced expiratory volume in 1 s (r = 0.66 and -0.77; both p<0.01) and Saint George's Respiratory Questionnaire (mucus: r = 0.45; p = 0.05).
conclusionsBenralizumab treatment in SEA was associated with early improvements in airway volume, resistance, mucus and air-trapping, correlating with better lung function and quality of life. These findings support FRI to monitor early treatment effects. TRIAL REGISTRATION NUMBER: NL-OMON26915.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.